In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

Filippatos G, Butler J, Farmakis D, et al. Circulation. 2022;146:676-86. 35762322.

Saved in:
Bibliographic Details
Published inAnnals of internal medicine Vol. 175; no. 10; p. JC111
Main Authors Fudim, Marat, Van Spall, Harriette G C
Format Journal Article
LanguageEnglish
Published United States 01.10.2022
Subjects
Benzhydryl Compounds
Diabetes Mellitus - drug therapy
Glucosides
Heart Failure - drug therapy
Hospitalization
Humans
Stroke Volume
Ventricular Function, Left
Online AccessGet more information

Cover

More Information
Summary:Filippatos G, Butler J, Farmakis D, et al. Circulation. 2022;146:676-86. 35762322.
ISSN:1539-3704
DOI:10.7326/J22-0075